# Revolution Medicines, Inc. is a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers.

*biotech · news · 2026-04-21 · The Manila Times*

## Key points

- Daraxonrasib showed unprecedented overall survival benefit in Phase 3 RASolute 302 trial for metastatic PDAC.
- Daraxonrasib met all primary and key secondary endpoints versus standard chemotherapy in treated metastatic PDAC.
- RASolute 302 trial included patients with diverse RAS variants, including those without identified RAS mutations.
- Daraxonrasib received FDA Breakthrough Therapy and Orphan Drug Designations for metastatic PDAC with G12 mutations.

**Companies:** Revolution Medicines, Inc.
**Countries:** United States

[Read the full story on The Manila Times](https://www.manilatimes.net/2026/04/21/tmt-newswire/globenewswire/revolution-medicines-to-present-pivotal-phase-3-rasolute-302-clinical-trial-results-for-daraxonrasib-in-previously-treated-metastatic-pancreatic-cancer-during-a-plenary-session-at-the-2026-asco-annual-meeting/2325318)

---

Canonical: https://newsio.io/n/a7928643-9902-4949-b85a-e704e139689b/revolution-medicines-inc-is-a-late-stage-clinical-oncology-company-developing-ta
Summarized by Newsio from The Manila Times. https://newsio.io/how-it-works